drugset / Trial / NCT00025480

Tipifarnib Plus Radiation Therapy After Combination Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer

NCT00025480

Treatment

Summary

RATIONALE: Tipifarnib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by making tumor cells more sensitive to radiation therapy. Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells either by killing the cells or by stopping them from dividing and may also make tumor cells more sensitive to radiation therapy. PURPOSE: This phase I trial is studying the side effects and best dose of tipifarnib when given together with radiation therapy after combination chemotherapy in treating patients with stage III non-small cell lung cancer.

Timeline

Start
2001-08
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject tipifarnib Small molecule Oral
Background Carboplatin Small molecule Intravenous
Background Paclitaxel Small molecule Intravenous

Indications